Evotec : Analyst presentation

Driving growth & Getting ready for launch

Evotec SE, H1 2021 Interim Report, 11 August 2021

Cautionary statement regarding forward-looking statements

Information set forth in this presentation contains forward-looking statements, which involve a number of risks and

uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate", "believe", "could", "estimate", "expect", "goal", "intend", "look forward to", "may", "plan", "potential", "predict", "project", "should", "will", "would" and similar expressions. The forward-looking statements

contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements.

Note:

The operating business of Evotec GT commenced on 1 April 2020. In addition, the acquisition of the assets (mainly land and buildings) and the takeover of employees of the Biopark by Sanofi SAS in Toulouse became legally effective on 1 July 2020. The two entities were fully consolidated in the consolidated financial statements from the dates specified above.

PAGE 1

Welcome to H1 2021

The Management Team

Werner Lanthaler1)

Enno Spillner1)

Craig Johnstone

Cord Dohrmann

CEO

CFO

COO

CSO

PAGE 2

1) On the call for the H1 2021 interim report

Agenda

Highlights

Financial performance H1 2021

"Building for growth"

Guidance 2021

PAGE 3

Strong overall performance and progress in all "lanes"

H1 2021 - Highlights & Lowlights

Highlights

• Business building accelerated, despite COVID-19
• Multiple new & extended integrated drug discovery and development alliances (EVOiR&D)
• J.POD® 1 US in Redmond opening August 18th;
  construction of J.POD® 2 EU to start in Q4 2021 (EVOaccess)
• Acquisition of Verona site completed - Now "Campus Levi-Montalcini"
• BMS Oncology protein degradation partnership - significant extension ahead of term
• New protein degradation collaboration in undisclosed therapeutic area also signed with BMS
• PRROTECT, an initiative for pandemic preparedness, launched
• Confidential submission of draft registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed offering of American Depositary Shares (after period-end)
• Positive Phase IIb results for Bayer's eliapixant in patients with refractory chronic cough (RCC) (after period-end) (EVOroyalty)

Lowlights

• Slight delays in milestones, but several important milestones imminent

PAGE 4